+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Prostate Cancer Therapeutics Market Size, Share & Trends Analysis Report by Drug Class (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy), Distribution Channel, and Region with Growth Forecasts, 2025-2030- Product Image
Prostate Cancer Therapeutics Market Size, Share & Trends Analysis Report by Drug Class (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy), Distribution Channel, and Region with Growth Forecasts, 2025-2030- Product Image
New

Prostate Cancer Therapeutics Market Size, Share & Trends Analysis Report by Drug Class (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy), Distribution Channel, and Region with Growth Forecasts, 2025-2030

  • PDF Icon

    Report

  • 100 Pages
  • February 2025
  • Region: Global
  • Grand View Research
  • ID: 4312504
Description Jump to:
The Prostate Cancer Therapeutics Market was valued at USD 13.4 billion in 2024, and is projected to reach USD 22.0 billion by 2030, rising at a CAGR of 8.60%. The market is expected to expand at a CAGR of 8.6% from 2025 to 2030. The growth of the market is attributed to the escalating prevalence of prostate cancer which in turn increases the demand for novel therapeutics. For instance, as per the ACS in 2022, prostate cancer is expected to have 268,490 new cases and lead to the death of 34,500 people worldwide. It affects roughly one out of every eight men at some point in their lives and is more common in older men.

A surge in government funding and increased public and private sector initiatives to enhance knowledge, and awareness about the availability of medicines amongst the public are projected to accelerate market growth. Furthermore, a rising preference for online drug purchasing over traditional methods, an increase in the number of internet users, and a rise in awareness regarding online pharmacies are expected to enhance the treatment adoption rate.

As per the American Cancer Society, in 2022, prostate cancer is the second leading cause of death in the male population of the U.S. Around one man in every 41 dies from prostate cancer. Although prostate cancer is a deadly disease, the mortality rate from the disease is low. The availability of a supportive regulatory landscape is expected to drive the adoption of novel products such as 177Lu-PSMA-617, which is precision medicine for patients that have not been cured with multiple rounds of treatment. The product received FDA approval in March 2022 for the treatment of mCRPC.

Targeted and biological therapy, chemotherapy, and hormonal therapy are some of the methods used to treat the condition. The high cost of targeted therapies and other immunotherapies is projected to act as a significant limitation on the global market. Low awareness of technological advancements in the therapeutic area in developing countries is expected to become a restrain for the market.

New trials are being conducted by institutes such as MRC Clinical Trials Unit at UCL. A June 2022, publication by the institute highlights secondary cancer tumor type of prostate cancer patients are benefited more from the use of chemotherapy such as docetaxel with an enhanced survival rate of 39%. These studies are creating a more effective way of providing a personalized medicine approach to prostate cancer patients so that they experience fewer side effects.

Prostate Cancer Therapeutics Market Report Highlights

  • By drug class, the hormonal therapy segment held the largest share and is expected to be the fastest-growing segment due to the availability and efficient mechanism of action for treating the diseased condition completely
  • Xtandi drug is expected to grow at the fastest rate over the forecast period due to the high adoption of the drug and usage of the drug for longer periods of time
  • North America dominated the market in 2024 and is anticipated to be the fastest-growing region owing to an increase in the disease's prevalence, and a strong need for prostate cancer therapeutic products in the region
  • Key market players operating in the market are focusing on developing novel products to meet the demand and provide efficient treatment options

This report addresses:

  • Market intelligence to enable effective decision-making.
  • Market estimates and forecasts from 2018 to 2030.
  • Growth opportunities and trend analyses.
  • Segment and regional revenue forecasts for market assessment.
  • Competition strategy and market share analysis.
  • Product innovation listings for you to stay ahead of the curve.
  • COVID-19's impact and how to sustain in this fast-evolving market.

Why Should You Buy This Report?

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Drug Class
1.2.2. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Prostate Cancer Therapeutics Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
Chapter 4. Prostate Cancer Therapeutics Market: Drug Class Business Analysis
4.1. Drug Class Market Share, 2024 & 2030
4.2. Drug Class Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
4.4. Hormonal Therapy
4.4.1. Hormonal Therapy Market, 2018-2030 (USD Million)
4.5. Chemotherapy
4.5.1. Chemotherapy Market, 2018-2030 (USD Million)
4.6. Immunotherapy
4.6.1. Immunotherapy Market, 2018-2030 (USD Million)
4.7. Targeted Therapy
4.7.1. Targeted Therapy Market, 2018-2030 (USD Million)
4.8. Others
4.8.1. Others Market, 2018-2030 (USD Million)
Chapter 5. Prostate Cancer Therapeutics Market: Distribution Channel Business Analysis
5.1. Distribution Channel Market Share, 2024 & 2030
5.2. Distribution Channel Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
5.4. Hospital Pharmacies
5.4.1. Hospital Pharmacies Market, 2018-2030 (USD Million)
5.5. Drug Stores & Retail Pharmacies
5.5.1. Drug Stores & Retail Pharmacies Market, 2018-2030 (USD Million)
5.6. Online Pharmacies
5.6.1. Online Pharmacies Market, 2018-2030 (USD Million)
Chapter 6. Prostate Cancer Therapeutics Market: Regional Estimates & Trend Analysis
6.1. Regional Market Share Analysis, 2024 & 2030
6.2. Regional Market Dashboard
6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
6.4. North America
6.4.1. North America Prostate Cancer Therapeutics Market Estimates And Forecasts, by Country, 2018-2030 (USD Million)
6.4.2. U.S.
6.4.2.1. Key Country Dynamics
6.4.2.2. Regulatory Framework
6.4.2.3. Competitive Insights
6.4.2.4. U.S. Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018-2030 (USD Million)
6.4.3. Canada
6.4.3.1. Key Country Dynamics
6.4.3.2. Regulatory Framework
6.4.3.3. Competitive Insights
6.4.3.4. Canada Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018-2030 (USD Million)
6.4.4. Mexico
6.4.4.1. Key Country Dynamics
6.4.4.2. Regulatory Framework
6.4.4.3. Competitive Insights
6.4.4.4. Mexico Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018-2030 (USD Million)
6.5. Europe
6.5.1. Europe Prostate Cancer Therapeutics Market Estimates And Forecasts, by Country, 2018-2030 (USD Million)
6.5.2. UK
6.5.2.1. Key Country Dynamics
6.5.2.2. Regulatory Framework
6.5.2.3. Competitive Insights
6.5.2.4. UK Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018-2030 (USD Million)
6.5.3. Germany
6.5.3.1. Key Country Dynamics
6.5.3.2. Regulatory Framework
6.5.3.3. Competitive Insights
6.5.3.4. Germany Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018-2030 (USD Million)
6.5.4. France
6.5.4.1. Key Country Dynamics
6.5.4.2. Regulatory Framework
6.5.4.3. Competitive Insights
6.5.4.4. France Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018-2030 (USD Million)
6.5.5. Italy
6.5.5.1. Key Country Dynamics
6.5.5.2. Regulatory Framework
6.5.5.3. Competitive Insights
6.5.5.4. Italy Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018-2030 (USD Million)
6.5.6. Spain
6.5.6.1. Key Country Dynamics
6.5.6.2. Regulatory Framework
6.5.6.3. Competitive Insights
6.5.6.4. Spain Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018-2030 (USD Million)
6.5.7. Norway
6.5.7.1. Key Country Dynamics
6.5.7.2. Regulatory Framework
6.5.7.3. Competitive Insights
6.5.7.4. Norway Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018-2030 (USD Million)
6.5.8. Denmark
6.5.8.1. Key Country Dynamics
6.5.8.2. Regulatory Framework
6.5.8.3. Competitive Insights
6.5.8.4. Denmark Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018-2030 (USD Million)
6.5.9. Sweden
6.5.9.1. Key Country Dynamics
6.5.9.2. Regulatory Framework
6.5.9.3. Competitive Insights
6.5.9.4. Sweden Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018-2030 (USD Million)
6.6. Asia Pacific
6.6.1. Asia Pacific Prostate Cancer Therapeutics Market Estimates And Forecasts, by Country, 2018-2030 (USD Million)
6.6.2. Japan
6.6.2.1. Key Country Dynamics
6.6.2.2. Regulatory Framework
6.6.2.3. Competitive Insights
6.6.2.4. Japan Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018-2030 (USD Million)
6.6.3. China
6.6.3.1. Key Country Dynamics
6.6.3.2. Regulatory Framework
6.6.3.3. Competitive Insights
6.6.3.4. China Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018-2030 (USD Million)
6.6.4. India
6.6.4.1. Key Country Dynamics
6.6.4.2. Regulatory Framework
6.6.4.3. Competitive Insights
6.6.4.4. India Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018-2030 (USD Million)
6.6.5. South Korea
6.6.5.1. Key Country Dynamics
6.6.5.2. Regulatory Framework
6.6.5.3. Competitive Insights
6.6.5.4. South Korea Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018-2030 (USD Million)
6.6.6. Australia
6.6.6.1. Key Country Dynamics
6.6.6.2. Regulatory Framework
6.6.6.3. Competitive Insights
6.6.6.4. Australia Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018-2030 (USD Million)
6.6.7. Thailand
6.6.7.1. Key Country Dynamics
6.6.7.2. Regulatory Framework
6.6.7.3. Competitive Insights
6.6.7.4. Thailand Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018-2030 (USD Million)
6.7. Latin America
6.7.1. Latin America Prostate Cancer Therapeutics Market Estimates And Forecasts, by Country, 2018-2030 (USD Million)
6.7.2. Brazil
6.7.2.1. Key Country Dynamics
6.7.2.2. Regulatory Framework
6.7.2.3. Competitive Insights
6.7.2.4. Brazil Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018-2030 (USD Million)
6.7.3. Argentina
6.7.3.1. Key Country Dynamics
6.7.3.2. Regulatory Framework
6.7.3.3. Competitive Insights
6.7.3.4. Argentina Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018-2030 (USD Million)
6.8. MEA
6.8.1. MEA Prostate Cancer Therapeutics Market Estimates And Forecasts, by Country, 2018-2030 (USD Million)
6.8.2. South Africa
6.8.2.1. Key Country Dynamics
6.8.2.2. Regulatory Framework
6.8.2.3. Competitive Insights
6.8.2.4. South Africa Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018-2030 (USD Million)
6.8.3. Saudi Arabia
6.8.3.1. Key Country Dynamics
6.8.3.2. Regulatory Framework
6.8.3.3. Competitive Insights
6.8.3.4. Saudi Arabia Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018-2030 (USD Million)
6.8.4. UAE
6.8.4.1. Key Country Dynamics
6.8.4.2. Regulatory Framework
6.8.4.3. Competitive Insights
6.8.4.4. UAE Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018-2030 (USD Million)
6.8.5. Kuwait
6.8.5.1. Key Country Dynamics
6.8.5.2. Regulatory Framework
6.8.5.3. Competitive Insights
6.8.5.4. Kuwait Prostate Cancer Therapeutics Market Estimates And Forecasts, 2018-2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Participant Overview
7.2. Company Market Position Analysis
7.3. Company Categorization
7.4. Strategy Mapping
7.5. Company Profiles/Listing
7.5.1. Johnson & Johnson Services, Inc.
7.5.1.1. Overview
7.5.1.2. Financial Performance
7.5.1.3. Product Benchmarking
7.5.1.4. Strategic Initiatives
7.5.2. Astellas Pharma Inc.
7.5.2.1. Overview
7.5.2.2. Financial Performance
7.5.2.3. Product Benchmarking
7.5.2.4. Strategic Initiatives
7.5.3. Eli Lilly and Company
7.5.3.1. Overview
7.5.3.2. Financial Performance
7.5.3.3. Product Benchmarking
7.5.3.4. Strategic Initiatives
7.5.4. Sanofi
7.5.4.1. Overview
7.5.4.2. Financial Performance
7.5.4.3. Product Benchmarking
7.5.4.4. Strategic Initiatives
7.5.5. Ipsen Pharma
7.5.5.1. Overview
7.5.5.2. Financial Performance
7.5.5.3. Product Benchmarking
7.5.5.4. Strategic Initiatives
7.5.6. Bayer AG
7.5.6.1. Overview
7.5.6.2. Financial Performance
7.5.6.3. Product Benchmarking
7.5.6.4. Strategic Initiatives
7.5.7. AstraZeneca
7.5.7.1. Overview
7.5.7.2. Financial Performance
7.5.7.3. Product Benchmarking
7.5.7.4. Strategic Initiatives
7.5.8. Bausch Health Companies Inc.
7.5.8.1. Overview
7.5.8.2. Financial Performance
7.5.8.3. Product Benchmarking
7.5.8.4. Strategic Initiatives
7.5.9. Merck & Co., Inc.
7.5.9.1. Overview
7.5.9.2. Financial Performance
7.5.9.3. Product Benchmarking
7.5.9.4. Strategic Initiatives
7.5.10. Pfizer Inc.
7.5.10.1. Overview
7.5.10.2. Financial Performance
7.5.10.3. Product Benchmarking
7.5.10.4. Strategic Initiatives
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global prostate cancer therapeutics market, by region, 2018-2030 (USD Million)
Table 4 Global prostate cancer therapeutics market, by drug class, 2018-2030 (USD Million)
Table 5 Global prostate cancer therapeutics market, by distribution channel, 2018-2030 (USD Million)
Table 6 North America prostate cancer therapeutics market, by country, 2018-2030 (USD Million)
Table 7 North America prostate cancer therapeutics market, by drug class, 2018-2030 (USD Million)
Table 8 North America prostate cancer therapeutics market, by distribution channel, 2018-2030 (USD Million)
Table 9 US prostate cancer therapeutics market, by drug class, 2018-2030 (USD Million)
Table 10 US prostate cancer therapeutics market, by distribution channel, 2018-2030 (USD Million)
Table 11 Canada prostate cancer therapeutics market, by drug class, 2018-2030 (USD Million)
Table 12 Canada prostate cancer therapeutics market, by distribution channel, 2018-2030 (USD Million)
Table 13 Mexico prostate cancer therapeutics market, by drug class, 2018-2030 (USD Million)
Table 14 Mexico prostate cancer therapeutics market, by distribution channel, 2018-2030 (USD Million)
Table 15 Europe prostate cancer therapeutics market, by country, 2018-2030 (USD Million)
Table 16 Europe prostate cancer therapeutics market, by drug class, 2018-2030 (USD Million)
Table 17 Europe prostate cancer therapeutics market, by distribution channel, 2018-2030 (USD Million)
Table 18 UK prostate cancer therapeutics market, by drug class, 2018-2030 (USD Million)
Table 19 UK prostate cancer therapeutics market, by distribution channel, 2018-2030 (USD Million)
Table 20 Germany prostate cancer therapeutics market, by drug class, 2018-2030 (USD Million)
Table 21 Germany prostate cancer therapeutics market, by distribution channel, 2018-2030 (USD Million)
Table 22 France prostate cancer therapeutics market, by drug class, 2018-2030 (USD Million)
Table 23 France prostate cancer therapeutics market, by distribution channel, 2018-2030 (USD Million)
Table 24 Italy prostate cancer therapeutics market, by drug class, 2018-2030 (USD Million)
Table 25 Italy prostate cancer therapeutics market, by distribution channel, 2018-2030 (USD Million)
Table 26 Spain prostate cancer therapeutics market, by drug class, 2018-2030 (USD Million)
Table 27 Spain prostate cancer therapeutics market, by distribution channel, 2018-2030 (USD Million)
Table 28 Norway prostate cancer therapeutics market, by drug class, 2018-2030 (USD Million)
Table 29 Norway prostate cancer therapeutics market, by distribution channel, 2018-2030 (USD Million)
Table 30 Denmark prostate cancer therapeutics market, by drug class, 2018-2030 (USD Million)
Table 31 Denmark prostate cancer therapeutics market, by distribution channel, 2018-2030 (USD Million)
Table 32 Sweden prostate cancer therapeutics market, by drug class, 2018-2030 (USD Million)
Table 33 Sweden prostate cancer therapeutics market, by distribution channel, 2018-2030 (USD Million)
Table 34 Asia Pacific prostate cancer therapeutics market, by country, 2018-2030 (USD Million)
Table 35 Asia Pacific prostate cancer therapeutics market, by drug class, 2018-2030 (USD Million)
Table 36 Asia Pacific prostate cancer therapeutics market, by distribution channel, 2018-2030 (USD Million)
Table 37 Japan prostate cancer therapeutics market, by drug class, 2018-2030 (USD Million)
Table 38 Japan prostate cancer therapeutics market, by distribution channel, 2018-2030 (USD Million)
Table 39 China prostate cancer therapeutics market, by drug class, 2018-2030 (USD Million)
Table 40 China prostate cancer therapeutics market, by distribution channel, 2018-2030 (USD Million)
Table 41 India prostate cancer therapeutics market, by drug class, 2018-2030 (USD Million)
Table 42 India prostate cancer therapeutics market, by distribution channel, 2018-2030 (USD Million)
Table 43 Australia prostate cancer therapeutics market, by drug class, 2018-2030 (USD Million)
Table 44 Australia prostate cancer therapeutics market, by distribution channel, 2018-2030 (USD Million)
Table 45 South Korea prostate cancer therapeutics market, by drug class, 2018-2030 (USD Million)
Table 46 South Korea prostate cancer therapeutics market, by distribution channel, 2018-2030 (USD Million)
Table 47 Thailand prostate cancer therapeutics market, by drug class, 2018-2030 (USD Million)
Table 48 Thailand prostate cancer therapeutics market, by distribution channel, 2018-2030 (USD Million)
Table 49 Latin America prostate cancer therapeutics market, by country, 2018-2030 (USD Million)
Table 50 Latin America prostate cancer therapeutics market, by drug class, 2018-2030 (USD Million)
Table 51 Latin America prostate cancer therapeutics market, by distribution channel, 2018-2030 (USD Million)
Table 52 Brazil prostate cancer therapeutics market, by drug class, 2018-2030 (USD Million)
Table 53 Brazil prostate cancer therapeutics market, by distribution channel, 2018-2030 (USD Million)
Table 54 Argentina prostate cancer therapeutics market, by drug class, 2018-2030 (USD Million)
Table 55 Argentina prostate cancer therapeutics market, by distribution channel, 2018-2030 (USD Million)
Table 56 Middle East & Africa prostate cancer therapeutics market, by country, 2018-2030 (USD Million)
Table 57 Middle East & Africa prostate cancer therapeutics market, by drug class, 2018-2030 (USD Million)
Table 58 Middle East & Africa prostate cancer therapeutics market, by distribution channel, 2018-2030 (USD Million)
Table 59 South Africa prostate cancer therapeutics market, by drug class, 2018-2030 (USD Million)
Table 60 South Africa prostate cancer therapeutics market, by distribution channel, 2018-2030 (USD Million)
Table 61 Saudi Arabia prostate cancer therapeutics market, by drug class, 2018-2030 (USD Million)
Table 62 Saudi Arabia prostate cancer therapeutics market, by distribution channel, 2018-2030 (USD Million)
Table 63 UAE prostate cancer therapeutics market, by drug class, 2018-2030 (USD Million)
Table 64 UAE prostate cancer therapeutics market, by distribution channel, 2018-2030 (USD Million)
Table 65 Kuwait prostate cancer therapeutics market, by drug class, 2018-2030 (USD Million)
Table 66 Kuwait prostate cancer therapeutics market, by distribution channel, 2018-2030 (USD Million)
List of Figures
Figure 1 Prostate Cancer Therapeutics market segmentation
Figure 2 Market research process
Figure 3 Data triangulation techniques
Figure 4 Primary research pattern
Figure 5 Market research approaches
Figure 6 Value-chain-based sizing & forecasting
Figure 7 Market formulation & validation
Figure 8 Market snapshot
Figure 9 Drug class and distribution channel outlook (USD Million)
Figure 10 Competitive landscape
Figure 11 Prostate cancer therapeutics market dynamics
Figure 12 Prostate cancer therapeutics market: Porter’s five forces analysis
Figure 13 Prostate cancer therapeutics market: PESTLE analysis
Figure 14 Prostate cancer therapeutics market: Drug class segment dashboard
Figure 15 Prostate cancer therapeutics market: Drug class market share analysis, 2024 & 2030
Figure 16 Hormonal therapy market, 2018-2030 (USD Million)
Figure 17 Chemotherapy market, 2018-2030 (USD Million)
Figure 18 Immunotherapy market, 2018-2030 (USD Million)
Figure 19 Targeted therapy market, 2018-2030 (USD Million)
Figure 20 Others market, 2018-2030 (USD Million)
Figure 21 Prostate cancer therapeutics market: Distribution channel segment dashboard
Figure 22 Prostate cancer therapeutics market: Distribution channel market share analysis, 2024 & 2030
Figure 23 Hospital pharmacies market, 2018-2030 (USD Million)
Figure 24 Drug stores & retail pharmacies market, 2018-2030 (USD Million)
Figure 25 Online pharmacies market, 2018-2030 (USD Million)
Figure 26 Prostate cancer therapeutics market revenue, by region
Figure 27 Regional marketplace: Key takeaways
Figure 28 Regional marketplace: Key takeaways
Figure 29 North America prostate cancer therapeutics market, 2018-2030 (USD Million)
Figure 30 U.S. country dynamics
Figure 31 U.S. prostate cancer therapeutics market, 2018-2030 (USD Million)
Figure 32 Canada country dynamics
Figure 33 Canada prostate cancer therapeutics market, 2018-2030 (USD Million)
Figure 34 Mexico country dynamics
Figure 35 Mexico prostate cancer therapeutics market, 2018-2030 (USD Million)
Figure 36 Europe prostate cancer therapeutics market, 2018-2030 (USD Million)
Figure 37 UK country dynamics
Figure 38 UK prostate cancer therapeutics market, 2018-2030 (USD Million)
Figure 39 Germany country dynamics
Figure 40 Germany prostate cancer therapeutics market, 2018-2030 (USD Million)
Figure 41 France country dynamics
Figure 42 France prostate cancer therapeutics market, 2018-2030 (USD Million)
Figure 43 Italy country dynamics
Figure 44 Italy prostate cancer therapeutics market, 2018-2030 (USD Million)
Figure 45 Spain country dynamics
Figure 46 Spain prostate cancer therapeutics market, 2018-2030 (USD Million)
Figure 47 Norway country dynamics
Figure 48 Norway prostate cancer therapeutics market, 2018-2030 (USD Million)
Figure 49 Sweden country dynamics
Figure 50 Sweden prostate cancer therapeutics market, 2018-2030 (USD Million)
Figure 51 Denmark country dynamics
Figure 52 Denmark prostate cancer therapeutics market, 2018-2030 (USD Million)
Figure 53 Asia Pacific prostate cancer therapeutics market, 2018-2030 (USD Million)
Figure 54 Japan country dynamics
Figure 55 Japan prostate cancer therapeutics market, 2018-2030 (USD Million)
Figure 56 China country dynamics
Figure 57 China prostate cancer therapeutics market, 2018-2030 (USD Million)
Figure 58 India country dynamics
Figure 59 India prostate cancer therapeutics market, 2018-2030 (USD Million)
Figure 60 Australia country dynamics
Figure 61 Australia prostate cancer therapeutics market, 2018-2030 (USD Million)
Figure 62 South Korea country dynamics
Figure 63 South Korea prostate cancer therapeutics market, 2018-2030 (USD Million)
Figure 64 Thailand country dynamics
Figure 65 Thailand prostate cancer therapeutics market, 2018-2030 (USD Million)
Figure 66 Latin America prostate cancer therapeutics market, 2018-2030 (USD Million)
Figure 67 Brazil country dynamics
Figure 68 Brazil prostate cancer therapeutics market, 2018-2030 (USD Million)
Figure 69 Argentina country dynamics
Figure 70 Argentina prostate cancer therapeutics market, 2018-2030 (USD Million)
Figure 71 MEA prostate cancer therapeutics market, 2018-2030 (USD Million)
Figure 72 South Africa country dynamics
Figure 73 South Africa prostate cancer therapeutics market, 2018-2030 (USD Million)
Figure 74 Saudi Arabia country dynamics
Figure 75 Saudi Arabia prostate cancer therapeutics market, 2018-2030 (USD Million)
Figure 76 UAE country dynamics
Figure 77 UAE prostate cancer therapeutics market, 2018-2030 (USD Million)
Figure 78 Kuwait country dynamics
Figure 79 Kuwait prostate cancer therapeutics market, 2018-2030 (USD Million)
Figure 80 Company categorization
Figure 81 Company market position analysis
Figure 82 Strategic framework

Companies Mentioned

The major companies profiled in this Prostate Cancer Therapeutics market report include:
  • Johnson & Johnson Services, Inc.
  • Astellas Pharma Inc.
  • Eli Lilly and Company
  • Sanofi
  • Ipsen Pharma
  • Bayer AG
  • AstraZeneca
  • Bausch Health Companies Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages100
PublishedFebruary 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 13.4 Billion
Forecasted Market Value ( USD ) by 2030 $ 22 Billion
Compound Annual Growth Rate8.6%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Prostate Cancer Therapeutics Market by Drug Class, Distribution Channel - Global Forecast 2025-2030 - Product Image

Prostate Cancer Therapeutics Market by Drug Class, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 199 Pages
  • Global
From
Prostate Cancer Therapeutics - Global Strategic Business Report - Product Image

Prostate Cancer Therapeutics - Global Strategic Business Report

  • Report
  • 212 Pages
  • Global
From
Castrate-resistant Prostate Cancer Market Size, Share & Trends Analysis Report By Therapy (Chemotherapy, Hormonal Therapy, Immunotherapy, Radiotherapy), By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Castrate-resistant Prostate Cancer Market Size, Share & Trends Analysis Report By Therapy (Chemotherapy, Hormonal Therapy, Immunotherapy, Radiotherapy), By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 90 Pages
  • Global
From
Prostate Cancer Therapeutics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2024 To 2032 - Product Image

Prostate Cancer Therapeutics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2024 To 2032

  • Report
  • 170 Pages
  • Global
From
Prostate Cancer - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Prostate Cancer - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.